Customized Solutions for Ankylosing Spondylitis Model Development and Preclinical Research

Clinical scores increased with age and were reduced by therapy.

Download

Ankylosing spondylitis (AS) is a chronic, progressive inflammatory rheumatic disease primarily affecting the sacroiliac joints and axial skeleton, often leading to spinal fusion, reduced mobility, and significant functional impairment.

As a preclinical research service provider dedicated to complex human diseases, comprehensive capabilities are offered across diagnostic development, therapeutic discovery, disease model engineering, and preclinical evaluation. For ankylosing spondylitis, Protheragen provides fully customizable model development services alongside integrated, end‑to‑end preclinical research support, from target validation to IND‑enabling studies.

Overview of Ankylosing Spondylitis Models

Essential for elucidating disease pathogenesis and evaluating therapeutic interventions, animal models of ankylosing spondylitis include several well‑validated options: proteoglycan‑induced spondylitis (PGIS), curdlan‑injected SKG mice, and spontaneous models such as aging DBA/1 mice. Each model recapitulates specific pathological features of AS, such as sacroliitis, enthesitis, spinal ankylosis, and peripheral arthritis, though no single system fully reproduces the entire human disease spectrum. Complementary use of these models allows targeted investigation of distinct disease phases, from early inflammation to structural bone fusion.

Applications of Ankylosing Spondylitis Models

Indispensable for translational research in axial spondyloarthritis, these models support a wide range of applications from molecular pathway dissection to preclinical therapeutic validation. These platforms enable researchers to elucidate the molecular mechanisms driving axial spondyloarthritis while serving as decision-critical tools for selecting lead candidates, identifying surrogate biomarkers, and de-risking development programs.

Pathogenesis Elucidation

Dissecting the roles of HLA‑B27 misfolding, ER stress, IL‑17/IL‑23 axis hyperactivation, TNF‑α‑driven entheseal inflammation, and aberrant Wnt/β‑catenin signaling in spinal ankylosis.

Target Validation

Confirming the functional contribution of specific targets (e.g., IL‑17A, IL‑23R) by genetic knockout, neutralizing antibodies, or selective small molecules in disease onset or progression.

Efficacy Screening

Evaluating anti-inflammatory and anti-ankylotic effects of novel therapeutics using clinical scoring, high-resolution histopathology, and micro-CT-based volumetric quantification of syndesmophyte formation.

Biomarker Discovery

Identifying serum or tissue-specific biomarkers that correlate with systemic inflammation, radiographic progression, or therapy response, facilitating the bench-to-bedside translation of drug candidates.

Workflow for Ankylosing Spondylitis Model Development

Consultation and Model Selection: Defining research objectives (inflammation‑dominant vs. bone fusion‑dominant phenotype) and recommending the optimal AS model.
Study Design and Protocol Approval: Determining animal strain, sex, age, induction protocols, group size, therapy regimens, and endpoint measures (clinical scores, histopathology, micro‑CT, immunohistochemistry).
Model Induction and Validation: Executing model generation (e.g., immunization with human proteoglycan or complete Freund’s adjuvant) and baseline characterization to confirm disease onset using weight‑bearing assessment, swelling scores, and radiographic screening.
In‑life Phase and Intervention: Administering test articles via oral, intravenous, subcutaneous, or intraperitoneal routes; monitoring body weight, clinical signs, and mobility.
Endpoint Data Collection: Performing terminal procedures including serum isolation, tissue harvest (spine, sacroiliac joints, hind paws), micro‑CT for bone volume and ankylosis quantification, and histopathology scoring.
Data Analysis and Reporting: Delivering comprehensive study reports with raw data, statistical analysis, histopathology slides, imaging files, and translational interpretations.

Integrated Preclinical Research Services for Ankylosing Spondylitis

Expanding beyond model generation, our platform provides comprehensive research solutions designed to support every stage of the AS drug discovery pipeline, ensuring that all datasets are high-quality and regulatory-compliant.

Diagnostics Development Services

Designing and validating multiplex assays to quantify systemic and tissue-specific AS biomarkers such as IL-17A, IL-23, and MMP-3; engineering companion diagnostics to facilitate precise patient stratification.

Therapeutic Development Services

Executing rigorous in vivo efficacy and pharmacodynamic studies; optimizing therapeutic delivery through dose-ranging, route-of-administration, and synergistic combination regimen evaluations in specialized AS systems.

Disease Model Development

Offering an extensive portfolio including PG‑induced spondylitis and Curdlan‑injected SKG models, plus custom development of AS models tailored to specific genetic or mechanistic needs.

Proteoglycan-Induced Model
Curdlan-induced SKG Mouse Model
Other Customized Models

Pharmacokinetics & Toxicology Evaluation

Conducting PK profiling and comprehensive safety pharmacology assessments to characterize the metabolic disposition, bioavailability, and potential dose-limiting toxicities of candidate compounds.

Case Study 01-Proteoglycan-Induced Spondylitis Model

A proteoglycan (PG)-induced spondylitis model was established in female BALB/c mice to evaluate the therapeutic potential of an investigational inhibitor. At week 0, mice received an intraperitoneal injection of PG mixed with dioctadecyldimethylammonium bromide (DDA) as an adjuvant, followed by booster injections at weeks 3 and 6. Starting at week 8, the test article or vehicle (control) was administered weekly. Body weight and arthritis severity were monitored throughout the 20-week study, with terminal collection of blood, joint tissues, and spine for downstream analyses, including micro-CT, immunohistochemistry, and cytokine profiling.

Timeline of PG injection, booster doses, test article administration, and terminal sample collection.

Fig.1 Experimental timeline for the proteoglycan-induced spondylitis model development.

Therapy with the inhibitor led to notable improvements in multiple disease parameters compared to the vehicle-treated model group. By week 20, body weight was better maintained, and peripheral arthritis severity was significantly reduced, characterized by attenuated synovial hyperplasia and reduced joint deformity. Serum levels of IL-17A, TNF-α, and IL-6 were all lower in the inhibitor-treated group as measured by ELISA. Micro‑CT analysis further demonstrated improved spinal bone structural parameters, indicating that the inhibitor mitigated signs of spinal fusion and pathological new bone formation.

Body weight trajectory and peripheral arthritis index at week 20.

Fig.2 Body weight and peripheral arthritis severity at week 20. Data are presented as mean ± SEM (n=5; ***p < 0.001, **p < 0.01).

Evaluation of serum cytokine concentrations (IL‑17A, TNF‑α, IL‑6).

Fig.3 Serum levels of inflammatory cytokines at week 20. Data are presented as mean ± SEM (n=5; ***p < 0.001, **p < 0.01).

Case Study 02-Curdlan-induced SKG Mouse Model

The SKG mouse, carrying a Zap70 W163C mutation on a BALB/c background, was used to model spondyloarthritis-like pathology. This mutation impairs ZAP-70 binding to CD3ζ ITAMs, attenuating TCR signaling and allowing autoreactive T cells to escape thymic negative selection. Following intraperitoneal injection of curdlan, SKG mice developed a chronic, IL-23/IL-17 axis-driven systemic autoimmune response that recapitulates key features of human spondyloarthropathies, including enthesitis, sacroiliitis, and peripheral arthritis. The present study compared disease progression in curdlan‑induced SKG mice versus wild‑type (BALB/c) controls.

Clinical arthritis scores in curdlan‑induced SKG mice versus wild‑type controls.

Fig.4 Clinical scores for joint swelling in experimental groups. Data are presented as mean ± SEM (Female, n=5).

Over the study period, curdlan‑induced SKG mice exhibited a gradual and significant elevation in clinical arthritis scores, whereas control mice maintained baseline scores. Progressive alterations in the right hind ankle joint were observed in curdlan‑induced SKG mice, with both joint width and thickness increasing significantly compared to wild‑type controls. Additional findings included markedly elevated serum IL-17A levels and extensive inflammatory cell infiltration in the colon, hind limb joints, and the spine on H&E staining at 8 weeks post-induction. These results confirm a robust autoimmune phenotype characterized by entheseal inflammation and pathological remodeling closely associated with IL-17A overexpression.

Time‑dependent increase in right hind ankle joint width and thickness following curdlan induction.

Fig.5 Changes in right hind ankle joint width and thickness in SKG mice and control mice. Data are presented as mean ± SEM (Female, n=5).

Why Choose Us?

Experience and Expertise: Decades of experience in autoimmune and inflammatory disease research, led by a dedicated team of scientists with a proven track record in AS model characterization and therapeutic testing.
Integrated Services: End-to-end support from disease model development to efficacy evaluation, seamlessly connecting study design, sample analysis, and data reporting to streamline the entire preclinical pipeline.
Innovative Platform: State-of-the-art technologies, including multi-omics profiling, high-resolution micro-CT imaging, and advanced immunophenotyping, enable deep mechanistic insights into AS pathology.
Customized Solutions: Tailored study designs that address specific research questions, incorporating variables such as genetic background, disease stage, or route of administration to maximize translational relevance.

Contact Us

Protheragen’s capabilities in ankylosing spondylitis model development and full‑spectrum preclinical research enable robust, translational data generation for both biologic and small‑molecule programs. From custom disease model engineering to validated diagnostic assays, therapeutic efficacy studies, and regulatory‑ready safety evaluations, every step is executed with scientific rigor and operational precision. For detailed proposals, model characterizations, or study design consultations, please contact our preclinical team.

Resource Download Request

Please complete the form to download the requested resources.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Disease Solutions

Resources

Online Inquiry